Evidence map›Paper›PMID 33143538›Full record

Trial reportJournal of psychopharmacology (Oxford, England)2020

Does anxiety moderate the effectiveness of mirtazapine in patients with treatment-resistant depression? A secondary analysis of the MIR trial.

Raphael Rifkin-Zybutz, Stephanie MacNeill, Simon Jc Davies, Christopher Dickens, John Campbell, Ian M Anderson, Carolyn A Chew-Graham, Tim J Peters, Glyn Lewis, Nicola Wiles and 1 more

Open access · hybridAbstract readMulticenter StudyPragmatic Clinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of psychopharmacology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 6 institutions in 2 countries.

Raphael Rifkin-ZybutzCentre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0003-1230-0847
Stephanie MacNeillCentre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.
Simon Jc DaviesCentre for Addiction and Mental Health, University of Toronto, Toronto, Canada.
Christopher DickensMental Health Research Group, University of Exeter, Exeter, UK.
John CampbellAcademic Primary Care, University of Exeter, Exeter, UK.
Ian M AndersonNeuroscience and Psychiatry Unit, University of Manchester, Manchester, UK.ORCID 0000-0003-2205-9209
Carolyn A Chew-GrahamSchool of Primary, Community and Social Care, Keele University, Keele, UK.
Tim J PetersCentre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.
Glyn LewisDivision of Psychiatry, University College London, London, UK.
Nicola WilesCentre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.
David KesslerCentre for Academic Mental Health, Bristol Medical School, University of Bristol, Bristol, UK.
University of Bristol · GBUniversity of Exeter · GBCentre for Addiction and Mental Health · CAKeele University · GBUniversity College London · GBUniversity of Manchester · GB

Funding

Department of Health 11/129/76
6 · The paper itself

Abstract

backgroundThere is a lack of evidence to guide treatment of comorbid depression and anxiety. Preliminary evidence suggests mirtazapine may be effective in treating patients with both depression and anxiety symptoms.

methodsWe undertook a secondary analysis of mirtazapine (MIR): a placebo-controlled trial of the addition of mirtazapine to a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor in treatment-resistant depression (TRD) in primary care. We subdivided participants into three groups by baseline generalized anxiety disorder score (GAD-7): severe (GAD-7 ⩾ 16), moderate (GAD-7 = 11-15), no/mild (GAD-7 ⩽ 10). We used linear regression including likelihood-ratio testing of interaction terms to assess how baseline anxiety altered the response of participants to mirtazapine as measured by 12-week GAD-7 and Beck Depression Inventory II (BDI-II) scores.

resultsBaseline generalized anxiety moderated mirtazapine's effect as measured by GAD-7 (

conclusionsThese findings extend the evidence for the effectiveness of mirtazapine to reduce generalized anxiety in TRD in primary care. These results may inform targeted prescribing in depression based on concurrent anxiety symptoms, although these conclusions are constrained by the post-hoc nature of this analysis.

Indexed as

AdultAgedAnti-Anxiety AgentsAnxiety DisordersComorbidityData Interpretation, StatisticalDepressive Disorder, Treatment-ResistantDrug Therapy, CombinationFemaleHumansMaleMiddle AgedMirtazapineOutcome Assessment, Health CarePrimary Health CareSelective Serotonin Reuptake InhibitorsAnti-Anxiety AgentsMirtazapineSelective Serotonin Reuptake InhibitorsSerotonin and Noradrenaline Reuptake Inhibitorsantidepressantsclinical trialsDepressionGADpharmacotherapytreatment resistance

Identifiers

PMID33143538
PMCPMC7708671
OpenAlexW3097469155

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.